Drugs / Anti-BCMA CAR T cells
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 02 trials | ||||||
| Phase 0 | NCT03943472 | Jul 2019 → Nov 2021 | plasma cell myeloma | Hrain Biotechnology Co., Ltd. | Unknown | No outcome recorded |
| Phase 0 | NCT03559764 | Jun 2018 → Feb 2020 | refractory plasma cell neoplasm | Allife Medical Science and Technology Co., Ltd. | Unknown | No outcome recorded |
| Phase 11 trial | ||||||
| Phase 1 | NCT05577000 | Oct 2021 → Nov 2025 overdue | plasma cell myeloma | Thomas Martin, MD | Active not recruiting | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT07477912 | Feb 2025 → Feb 2028 expected | plasma cell myeloma | Minsk Scientific-Practical Center for Surgery, Transplantation and Hematology | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | anti BCMA CAR-T cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07477912 ↗ |
| Known as | Manufactured Anti-BCMA CAR-T cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05577000 ↗ |
| Modality | Cell therapy | “CAR - T cells was taken in the form of genetic modification” NCT03559764 ↗ |